Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

NCT02396316 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Neovascular

Interventions

DRUG: Aflibercept (Eylea, BAY 86-5321)
DRUG: Sham Injection

Sponsor

Bayer

Collaborators

[object Object]